You are here: Home » News-CM » Companies » News
Business Standard

Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA

Capital Market 

announced that the of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Inc., USA (now part of Group) at has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI).

The had completed the USFDA audit from 5 to 12 April, 2018.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, July 12 2018. 13:08 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU